10 hasil untuk "Manolis, Efthymios"
Menampilkan 1–10 · 0,20 detik · RSS
-
Artikel Jurnal Teks lengkap
Proposals for model-based paediatric medicinal development within the current European Union regulatory framework
The new paediatric European Union (EU) regulation and the consequent demand for paediatric studies on one hand and the ethical need for minimizing the burden of studies in children on the other hand necessitate optimal techniques in the assessment of safety/efficacy and use of drugs in children…
-
Artikel Jurnal Teks lengkap
Current Use of Physiologically Based Pharmacokinetic modeling in New Medicinal Product Approvals at EMA
Physiologically Based Pharmacokinetic (PBPK) Models are routinely used in drug development and therefore appear frequently in marketing authorization applications (MAAs) to the European Medicines Agency (EMA). For a model to be a key source of evidence for a regulatory decision, it must be…
-
Artikel Jurnal Teks lengkap
Model‐Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives
Good practices around model‐informed drug discovery and development (MID3) aim to improve the implementation, standardization, and acceptance of these approaches within drug development and regulatory review. A survey targeted to clinical pharmacology and pharmacometric colleagues across industry…
-
Artikel Jurnal Teks lengkap
Commentary on the EMA Reflection Paper on the use of extrapolation in the development of medicines for paediatrics
Adopted guidelines reflect a harmonised European approach to a specific scientific issue and should reflect the most recent scientific knowledge. However, whilst EU regulations are mandatory for all member states and EU directives must be followed by national laws in line with the directive, EMA…
-
Artikel Jurnal Teks lengkap
Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility
The value of in silico methods in drug development and evaluation has been demonstrated repeatedly and convincingly. While their benefits are now unanimously recognized, international standards for their evaluation, accepted by all stakeholders involved, are still to be established. In this white…
-
Artikel Jurnal Teks lengkap
Commentary on the MID3 Good Practices Paper
During the last 10 years the European Medicines Agency (EMA) organized a number of workshops on modeling and simulation, working towards greater integration of modeling and simulation (M&S) in the development and regulatory assessment of medicines. In the 2011 EMA – European Federation of…
-
Artikel Jurnal Teks lengkap
Implementation of proteomic biomarkers: making it work
While large numbers of proteomic biomarkers have been described, they are generally not implemented in medical practice. We have investigated the reasons for this shortcoming, focusing on hurdles downstream of biomarker verification, and describe major obstacles and possible solutions to ease valid…